XTX Topco Ltd Has $686,000 Stock Position in Exact Sciences Co. (NASDAQ:EXAS)

XTX Topco Ltd lessened its holdings in shares of Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 55.4% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 12,217 shares of the medical research company's stock after selling 15,155 shares during the period. XTX Topco Ltd's holdings in Exact Sciences were worth $686,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Advisors Capital Management LLC bought a new position in Exact Sciences in the fourth quarter valued at about $515,000. Sterling Capital Management LLC boosted its holdings in Exact Sciences by 40.6% in the fourth quarter. Sterling Capital Management LLC now owns 7,759 shares of the medical research company's stock valued at $436,000 after acquiring an additional 2,242 shares during the last quarter. Harbert Fund Advisors Inc. bought a new position in Exact Sciences in the fourth quarter valued at about $702,000. Kennedy Capital Management LLC boosted its holdings in Exact Sciences by 10.2% in the fourth quarter. Kennedy Capital Management LLC now owns 147,459 shares of the medical research company's stock valued at $8,286,000 after acquiring an additional 13,600 shares during the last quarter. Finally, Treasurer of the State of North Carolina boosted its holdings in Exact Sciences by 0.6% in the fourth quarter. Treasurer of the State of North Carolina now owns 80,216 shares of the medical research company's stock valued at $4,507,000 after acquiring an additional 500 shares during the last quarter. Institutional investors own 88.82% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on EXAS shares. Mizuho started coverage on Exact Sciences in a report on Thursday, April 10th. They issued an "outperform" rating and a $60.00 price target on the stock. William Blair restated an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Guggenheim restated a "buy" rating and set a $60.00 target price on shares of Exact Sciences in a report on Friday, April 11th. Barclays reduced their target price on Exact Sciences from $65.00 to $55.00 and set an "overweight" rating on the stock in a report on Thursday, April 10th. Finally, Benchmark restated a "buy" rating and set a $65.00 target price on shares of Exact Sciences in a report on Monday, January 13th. Two research analysts have rated the stock with a hold rating, nineteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Exact Sciences currently has a consensus rating of "Moderate Buy" and an average price target of $69.25.

Exact Sciences Stock Up 1.8 %

Exact Sciences stock traded up $0.78 during midday trading on Wednesday, reaching $44.93. The stock had a trading volume of 575,066 shares, compared to its average volume of 2,604,722. The firm's fifty day simple moving average is $45.60 and its 200-day simple moving average is $54.62. Exact Sciences Co. has a 1-year low of $39.97 and a 1-year high of $72.83. The stock has a market capitalization of $8.35 billion, a P/E ratio of -8.07 and a beta of 1.14. The company has a debt-to-equity ratio of 0.97, a quick ratio of 1.93 and a current ratio of 2.15.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last announced its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.29) by $0.23. The business had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. As a group, analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.